Inducible phosphofructokinase and the warburg effect
AssigneeThe Picower Institute for Medical Research
InventorsRichard J. Bucala, Jason A. Chesney, Robert A. Mitchell
Life of this patent
Estimating the term…
Abstract
There is disclosed a cancer malignancy diagnostic assay comprising obtaining a sample of a body fluid or tissue, performing a sequence identity assay to look for the presence of iPFK-2 specific sequences; an anticancer pharmaceutical composition comprising a specific antisense oligonucleotide to the inventive isolated iPFK-2 sequence and a pharmaceutically acceptable oligonucleotide carrier; and a method for finding therapeutically active anti-cancer compounds comprising screening compounds for activity to inhibit iPFK-2, preferably kinase activity.
Claims2
A method for screening for a candidate therapeutic agent that inhibits kinase enzymatic activity of iPFK-2, comprising:
- (a) expressing an iPFK-2 enzyme or kinase domain thereof from the cDNA sequence of SEQ ID NO. 11;
- (b) purifying and isolating the expressed iPFK-2 enzyme or kinase domain thereof;
- (c) providing a test compound that is a candidate therapeutic agent and fructose 6-phosphate substrate;
- and
- (d) measuring formation of fructose 2,6-bisphosphate product as a measure of the kinase enzymatic activity, wherein a reduction of kinase enzymatic activity compared to a control assay that does not include said test compound identifies a candidate therapeutic agent.
Dependencies are inferred from the claim text.